Newsroom

Sorted by: Latest

-

GPRO Stock Alert: Halper Sadeh LLC is Investigating Whether GoPro, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of GoPro, Inc. (NASDAQ: GPRO) to Starman Optical, Inc. for $1.14 per share, subject to potential adjustment based on GoPro’s net working capital at closing. Halper Sadeh encourages GoPro shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investig...
-

Semtech Brings 5G Network Slicing, FIPS 140-3 to IACP 2026

CAMARILLO, Calif.--(BUSINESS WIRE)--Semtech Corporation (Nasdaq: SMTC), a leading provider of high-performance semiconductors powering AI data center networking and intelligent, connected Internet of Things (“IoT”) devices worldwide, is adding new resilient communications building blocks to its AirLink® 5G Networking Solutions. Semtech will demonstrate the new capabilities in booth #2964 at the International Association of Chiefs of Police (IACP) conference in Orlando, Fla. First responders rel...
-

ESMO 2026: NUBEQA® (darolutamide) Plus ADT and Radiation Therapy Reduces Risk of Metastasis or Death by 58% in Prostate Cancer Patients at High Risk of Recurrence

WHIPPANY, N.J.--(BUSINESS WIRE)--ESMO 2026: NUBEQA® plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence...
-

Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

COPENHAGEN, Denmark & WILMINGTON, Del.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor receptor (EGFR) and leucine-rich repeat containing G-protein-coupled receptor 5 (LGR5), in combination with INCB161734, Incyte’s investigational, potent and selective KRAS G12D inhibitor, and standard-of-care chemotherapy as a fi...
-

Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer

WILMINGTON, Del. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer...
-

ライフゾーン・メタルズ、カバンガ・ニッケル・プロジェクトを巡るOrion CMCとの交渉がかなり進展していることを確認

ニューヨーク--(BUSINESS WIRE)--(ビジネスワイヤ) -- ライフゾーン・メタルズ・リミテッド(NYSE:LZM)は、オリオン・リソース・パートナーズの創業者兼グループ最高経営責任者であるOskar Lewnowski氏が、タンザニアにおけるライフゾーン・メタルズの「カバンガ・ニッケル・プロジェクト」に関してブルームバーグテレビジョンのインタビューで述べた内容についてお知らせします。 インタビュー後にメディアや投資家から寄せられた問い合わせを受け、ライフゾーン・メタルズは、カバンガ・ニッケル・プロジェクトへの大規模な出資を巡るオリオン重要鉱物コンソーシアム(Orion CMC)との交渉がかなり進展していることを確認しました。 Orion CMCは、オリオン・リソース・パートナーズが米国国際開発金融公社(DFC)およびアブダビの政府系投資会社ADQと提携して立ち上げたグローバル投資プラットフォームです。 既に発表しているとおり、ライフゾーン・メタルズは、カバンガ・ニッケル・プロジェクトへの戦略的投資を確保するため、スタンダードチャータード銀行が主導する競争的プロセスを進...
-

CatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit of PD-1 Inhibition in Neoadjuvant Bladder Cancer at ESMO 2026

MUNICH & SAN FRANCISCO--(BUSINESS WIRE)--CatalYm today announced final results from its randomized Phase 2 GDFATHER-NEO trial, which were presented in a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 and simultaneously published in Nature Medicine. The data showed that Growth Differentiation Factor-15 (GDF-15) blockade with visugromab substantially enhanced the anti-tumor activity of the PD‑1 inhibitor nivolumab in the neoadjuvant treatment of patients with...
-

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph....
-

Slate Grocery REIT Announces Receipt of Interim Order, and Provides Meeting and Circular Details

TORONTO--(BUSINESS WIRE)--Slate Grocery REIT (TSX: SGR.U) (TSX: SGR.UN) (the “REIT”), an owner and operator of U.S. grocery-anchored real estate, announced today that it has obtained an interim order (the “Interim Order”) of the Ontario Superior Court of Justice (Commercial List) (the “Court”) in connection with the proposed acquisition by EP/BRX Holdings LLC (the “Purchaser”), a joint venture between an affiliate of Brixmor Property Group Inc. and affiliates of Everview Partners, L.P., of all...
-

Deux machines haut de gamme de découpe laser de tubes font leurs débuts en Europe : Bodor Laser présente des solutions complètes de fabrication métallique à l’EuroBLECH 2026

HANOVRE, Allemagne--(BUSINESS WIRE)--Bodor Laser présentera deux nouvelles machines haut de gamme de découpe laser de tubes à l’EuroBLECH 2026, qui feront leurs débuts européens lors du plus grand salon mondial dédié à l’usinage de la tôle. L’événement se tiendra du 20 au 23 octobre à Hanovre. Bodor Laser sera présent dans le hall 13, aux stands A181 et A182, sur une surface d’exposition de plus de 1 400 m². Ces deux nouvelles machines offrent des solutions distinctes pour améliorer la producti...